Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19

Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19

Bibliographic Details
Main Authors:	Azadeh Khalili, Hosein Karim, Gholamreza Bayat
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2021-07-01
Series:	Iranian Journal of Medical Sciences
Subjects:	ace inhibitors angiotensin receptor antagonists covid-19
Online Access:	https://ijms.sums.ac.ir/article_47458_9c2e34be73233d10e6e50694a2b06835.pdf

Similar Items

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
by: Michael Pan, et al.
Published: (2021-12-01)

Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
by: Renata Aiglova, et al.
Published: (2022-09-01)

Synthesis of angiotensin-converting enzyme (ACE) inhibitors: an important class of antihypertensive drugs
by: Lima Dênis Pires de
Published: (1999-01-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND PROTEINURIA
by: Tanja Kök, et al.
Published: (2002-03-01)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes
by: Kevin Bryan Lo, et al.
Published: (2021-03-01)

Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
by: Rami Sommerstein, et al.
Published: (2020-04-01)

The renin-angiotensin system and its blockers
by: Igić Rajko, et al.
Published: (2014-01-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

New Users of Angiotensin II Receptor Blocker–Versus Angiotensin‐Converting Enzyme Inhibitor–Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD‐BP and SPRINT
by: Jordan B. King, et al.
Published: (2023-09-01)

Angiotensin converting enzyme inhibitors /
by: DeBrue, Anne N.
Published: (c200)

Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – Demystifying controversies
by: Kader Muneer, et al.
Published: (2017-05-01)

CORRELATION BETWEEN ANGIOTENSIN-CONVERTING ENZYME INHIBITORS LIPOPHILICITY AND PROTEIN BINDING DATA
by: Jasna Trbojević-Stanković, et al.
Published: (2012-01-01)

Angiotensin receptor blocker-induced bilateral ciliochoroidal effusion
by: Kanika Aggarwal, et al.
Published: (2020-01-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells
by: Oghenemega Okoloko, et al.
Published: (2021-11-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
by: Carlos P. Vio, et al.
Published: (2020-06-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND ACE INHIBITORS: OPTIMIZATION OF CHOICE FOR TREATMENT OF CARDIOVASCULAR DISEASES
by: E. M. Khurs, et al.
Published: (2016-01-01)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01)

Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions
by: Athanasios Feidakis, et al.
Published: (2021-01-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE
by: O. D. Ostroumova, et al.
Published: (2015-09-01)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
by: Valentina Carubelli, et al.
Published: (2021-06-01)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality of Coronary Artery Bypass Grafting
by: Ahmad Sharafi, et al.
Published: (2015-10-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

ADVANTAGES OF COMBINATION THERAPY OF HYPERTENSION WITH CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IN PATIENTS WITH IMPAIRED RENAL FUNCTION
by: N. A. Dzhaiani
Published: (2015-09-01)

Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease
by: Pei-Tzu Wang, et al.
Published: (2012-09-01)

Angiotensin Converting Enzyme Inhibitors versus Receptor Blockers in Patients with Ventricular Tachyarrhythmias
by: Tobias Schupp, et al.
Published: (2022-03-01)

Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
by: Marie Douillard, MD, et al.
Published: (2023-08-01)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Paweł Bryniarski, et al.
Published: (2022-02-01)

Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication
by: Jae Hoon Kim, et al.
Published: (2017-03-01)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Inflammatory Response and Viral Clearance in COVID-19 Patients
by: Linna Huang, et al.
Published: (2021-08-01)

Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients
by: Guasti L, et al.
Published: (2017-08-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2022-12-01)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
by: Darcy Adin, et al.
Published: (2020-03-01)